These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21265391)

  • 1. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.
    Avritscher EB; Shih YC; Sun CC; Gralla RJ; Grunberg SM; Xu Y; Elting LS
    J Support Oncol; 2010; 8(6):242-51. PubMed ID: 21265391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
    Suzuki C; Hiura K; Sato H; Komori H; Yamamoto M
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1653-7. PubMed ID: 21996961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
    Damian S; Celio L; De Benedictis E; Mariani P; Agustoni F; Ricchini F; De Braud F
    Oncology; 2013; 84(6):371-7. PubMed ID: 23711719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
    Nakayama Y; Ito Y; Tanabe M; Takahashi S; Hatake K
    Breast Cancer; 2015 Mar; 22(2):177-84. PubMed ID: 23653153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
    Matsuura M; Satohisa S; Teramoto M; Tanaka R; Iwasaki M; Nishikawa A; Mizunuma M; Tanaka S; Hayakawa O; Saito T
    J Obstet Gynaecol Res; 2015 Oct; 41(10):1607-13. PubMed ID: 26199182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
    Chan SL; Jen J; Burke T; Pellissier J
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
    Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.
    Kashiwa M; Matsushita R
    BMC Health Serv Res; 2019 Jul; 19(1):438. PubMed ID: 31262292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK; Wu CE; Liaw CC
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Herrington JD; Jaskiewicz AD; Song J
    Cancer; 2008 May; 112(9):2080-7. PubMed ID: 18327813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.